Archiv
Archiv anzeigen:
bis


Ibrutinib plus Venetoclax for Chronic Lymphocytic Leukemia

Michael E. Williams, MD, ScM reviewing Jain N et al. N Engl J Med 2019 May 30

The combination therapy provided a high remission rate in previously untreated older and high-risk patients.


Fractionated Radiotherapy for Prostate Cancer: Current Status

Robert Dreicer, MD, MS, MACP, FASCO reviewing Widmark A et al. Lancet 2019 Jun 18, Catton C and Lukka H. Lancet 2019 Jun 18

An ultra-hypofractionated approach was found noninferior to conventional hypofractionation but was accompanied by more urinary-tract and bowel symptoms.


Docetaxel Fails to Improve Survival as Part of First-Line Chemotherapy in Gastric Cancer

David H. Ilson, MD, PhD reviewing Yamada Y et al. Lancet Gastroenterol Hepatol 2019 Jul

Cisplatin and S-1 remain the standard, based on phase III trial results.


Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

David H. Ilson, MD, PhD reviewing Golan T et al. N Engl J Med 2019 Jun 2

The PARP inhibitor improved progression-free survival and durable response.


Inhibition of Sickle Hemoglobin Polymerization in Patients with Sickle Cell Anemia

Brady L. Stein, MD, MHS reviewing Vichinsky E et al. N Engl J Med 2019 Jun 14, Thompson A. N Engl J Med 2019 Jun 14

Investigational agent voxelotor significantly increased hemoglobin levels and reduced hemolysis compared with placebo.


Adjuvant S-1 plus Docetaxel for Stage III Gastric Cancer

David H. Ilson, MD, PhD reviewing Yoshida K et al. J Clin Oncol 2019 May 20

Relapse-free survival was significantly improved with S-1 plus docetaxel compared with S-1 alone.


ASCO 2019 Report — Hematologic Malignancy Highlights

Michael E. Williams, MD, ScM

Highlights of new treatments for myeloma and lymphoma


ASCO 2019 Report — Breast Cancer

William J. Gradishar, MD

Highlights of the latest treatments


ASCO 2019 Report — Lung Cancer

Anne S. Tsao, MD

Highlights of new treatments for patients with non–small-cell and small-cell lung cancer


ASCO 2019 Report — Genitourinary Cancer

Robert Dreicer, MD, MS, MACP, FASCO

Highlights of the latest treatments for urothelial and prostate cancers


Archiv
Seite von 83
Editorial Member Board Empfehlungen

Prof. Dr. med. Christoph Rochlitz

Chefarzt Onkologie
Universitätsspital Basel

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

In der vorliegenden Ausgabe von NEJM Journal Watch möchte ich Ihnen gerne wieder einige rezent publizierte Studien aus dem Bereich Onkologie/Hämatologie näherbringen.

Kommentar weiterlesen

Maintenance Immunotherapy for Mantle Cell Lymphoma

Michael E. Williams, MD, ScM reviewing Le Gouill S et al. N Engl J Med 2017 Sep 28

The use of rituximab following consolidation therapy and autologous stem cell transplantation significantly improved patient outcomes.


Adding Lorazepam to Haloperidol Might Help Alleviate Agitated Delirium in Advanced-Cancer Patients

Thomas L. Schwenk, MD reviewing Hui D et al. JAMA 2017 Sep 19, Pandharipande PP and Ely EW. JAMA 2017 Sep 19

Short-term reductions in agitation were helpful, but other components of delirium need further study.


Consolidation Immunotherapy After Chemoradiation for Advanced Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Antonia SJ et al. N Engl J Med 2017 Sep 8

Adding durvalumab to standard therapy significantly improved outcomes, but longer follow-up is required.


Axillary Dissection Unnecessary in Breast Cancer Patients with Positive Sentinel Lymph Nodes

Henry Mark Kuerer, MD, PhD, FACS reviewing Giuliano AE et al. JAMA 2017 Sep 12, Livingston EH and Li HC. JAMA 2017 Sep 12

Long-term results confirm that survival is noninferior with sentinel versus axillary dissection.


Neoadjuvant Chemotherapy for Esophageal Adenocarcinoma

David H. Ilson, MD, PhD reviewing Alderson D et al. Lancet Oncol 2017 Sep

More intense preoperative chemotherapy fails to improve survival.


Nivolumab for Metastatic MSI-High/dMMR Colorectal Cancer

David H. Ilson, MD, PhD reviewing Overman MJ et al. Lancet Oncol 2017 Sep

The anti-PD-1 agent nivolumab was active in biomarker-defined patients with microsatellite instability-high or DNA mismatch repair-deficient disease.


Does Cutting Dietary Fat Affect Breast Cancer Outcomes?

Andrew M. Kaunitz, MD reviewing Chlebowski RT et al. J Clin Oncol 2017 Sep 1

Women's Health Initiative randomized trial findings suggest lowering dietary fat also lowers mortality after breast cancer.


Prothrombin Complex Concentrate for Bleeding from Direct Oral Anticoagulants

David Green, MD, PhD reviewing Majeed A et al. Blood 2017 Aug 23

Treatment was effective for 70% of hemorrhages associated with apixaban or rivaroxaban.


Lung Cancer Rates Are Increasing Among Never-Smokers

Anne S. Tsao, MD reviewing Pelosof L et al. J Natl Cancer Inst 2017 Jul

From 1990 through 2013, the percentage of patients with non–small-cell lung cancer who never smoked rose from 8.0% to 14.9%.


Neoadjuvant CDK4/6 Inhibition for ER-Positive Breast Cancer

William J. Gradishar, MD reviewing Ma CX et al. Clin Cancer Res 2017 Aug 1

Palbociclib demonstrated activity in early-stage disease resistant to endocrine therapy, but prolonged exposure may be required.